Tradestie Institutional Equity Comparison Engine

NTLA vs AUPH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AUPH Overall Edge

AUPH Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aurinia Pharmaceuticals Inc (AUPH) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus AUPH at 13.6x Forward P/E and 51.6% operating margin (+13.9% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against AUPH sits in CONSOLIDATION (48th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AUPH
NTLA N/M vs AUPH 13.6x Fwd P/E
Growth & Margin Winner AUPH
Op Margin -826.0% vs 51.6% ยท YoY -48.0% vs +13.9%
Momentum & Technical Winner NTLA
1Y +15.3% vs +1.7% ยท 52W Pos 20% vs 34%
Options & Structure Winner AUPH
BREAKDOWN (78th %ile IV) vs CONSOLIDATION (48th %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
1M Return -12.43%
1Y Return +15.34%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
AUPH NASDAQ
Aurinia Pharmaceuticals Inc
Pharmaceutical Preparations
$15.47
-1.62% 1D
Market Cap $2.1B
1M Return -6.27%
1Y Return +1.68%
Forward P/E 13.6x
Unified AI Score
55.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +15.34% AUPH +1.68% Spread: +13.66 pp (NTLA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NTLA Revenue AUPH Revenue NTLA Op. Margin AUPH Op. Margin Margin Edge
FY2018 $30M $0M -298.6% -11930.9% NTLA
FY2019 $40M $0M -246.8% -28598.4% NTLA
FY2020 $60M $50M -235.5% -208.1% AUPH
FY2021 $30M $50M -810.4% -396.3% AUPH
FY2022 $50M $130M -879.0% -83.2% AUPH
FY2023 $40M $180M -1420.5% -52.2% AUPH
FY2024 $60M $240M -923.1% -2.0% AUPH
FY2025 $70M $280M -651.7% 37.1% AUPH

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (0) vs AUPH (10)
Institutional Metric NTLA AUPH Criterion Row Winner
Market Capitalization Scale $1.5B $2.1B Larger Scale AUPH
Trailing P/E Ratio Valuation N/M 7.0x Lower Multiple AUPH
Forward P/E Ratio Valuation N/M 13.6x Lower Multiple AUPH
Revenue Growth (YoY) Growth -48.0% +13.9% Higher Growth AUPH
Operating Margin (TTM) Profitability -826.0% 51.6% Higher Margin AUPH
Net Profit Margin Profitability 0.0% 97.7% Higher Margin AUPH
Return on Equity (ROE) Capital Efficiency -62.6% 61.4% Higher ROE AUPH
52-Week Range Position Momentum 20% ($8โ€“$18) 34% ($14โ€“$19) Stronger Trend AUPH
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 0.67ฮฒ ยท 36% Vol Lower Realized Risk AUPH
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 55.7 / 100 (HOLD) Higher Composite AUPH

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs AUPH Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AUPH CONSOLIDATION
101d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 48th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AUPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor AUPH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.